We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Futura Medical
FM71 achieves all primary and secondary endpointsArecor Therapeutics
Acquisition of Tetris Pharma and £6m equity raiseANGLE
£20m raise funds commercialisation through to mid-2024Allergy Therapeutics
Key data on track, return to growth expected next yearAvacta
AVA6000 set for third dose escalation stageRedx Pharma
All the ingredients for success now in placeRedx Pharma
Jazz Pharmaceuticals $5m milestone triggeredScancell
First Moditope oncology vaccine enters the clinicRedx Pharma
£34.3m raise extends runway through key data pointsArecor Therapeutics
AT278 hits the sweet spot